Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma

JAMA

Volumn 277, Issue 9, 1997, Pages 722-727

  Garbe, Edeltraut ^a,b   LeLorier, Jacques ^c   Boivin, Jean Francois ^a   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; FLUNISOLIDE; FLUTICASONE; GLUCOCORTICOID; TRIAMCINOLONE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS;

EID: 0031044736     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.277.9.722     Document Type: Article

References (46)

1. Habbick B, Baker MJ, McNutt M, Cockcroft DW. Recent trends in the use of inhaled beta2-adrenergic agonists and inhaled corticosteroids in Saskatchewan. Can Med Assoc J. 1995;153:1437-1443.
2. McManus P, Birkett D. Recent trends in the use of antiasthmatic drugs. Med J Aust. 1993;159:831-832.
3. Reed CE. Aerosol glucocorticoid treatment of asthma. Am Rev Respir Dis. 1990;141(suppl):S82-S88.
4. Mabry RL. Corticosteroids in the management of upper respiratory allergy: the emerging role of steroid nasal sprays. Otolaryngol Head Neck Surg. 1992;107:855-860.
5. Estelle F, Simons R, Simons KJ. Optimum pharmacological management of chronic rhinitis. Drugs. 1989;38:313-331.
6. Opatowsky I, Feldman RM, Gross R, Feldman ST. Intraocular pressure elevation associated with inhalation and nasal corticosteroids. Ophthalmology. 1995;102:177-179.
7. Jackson RV, Bowman RV. Corticosteroids. Med J Aust. 1995;162:663-665.
8. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332:868-875.
9. Barnes NC. Safety of high-dose inhaled corticosteroids. Respir Med. 1993;87(suppl A):27-31.
10. Dreyer EB. Inhaled steroid use and glaucoma. N Engl J Med. 1993;329:1822.
11. Skuta GL, Morgan RK. Corticosteroid-induced glaucoma. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. St Louis, Mo: Mosby-Year Book Inc; 1996:1177-1188.
12. Armaly MF. Corticosteroid glaucoma. In: Cairns JE, ed. Glaucoma. London, England: Grune & Stratton; 1986:697-710.
13. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48:999-1009.
14. World Health Organization. International Classification of Diseases, Ninth Revision (ICD-9). Geneva, Switzerland: World Health Organization; 1977.
15. Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1992;44:375-407.
16. Brogden RN, Heel RC, Speight TM, Avery GS. Beclomethasone diproprionate: a reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs. 1992;28:99-126.
17. Leske MC. The epidemiology of open-angle glaucoma: a review. Am J Epidemiol. 1983;118:166-191.
18. Wilson MR. Epidemiological features of glaucoma. Int Ophthalmol Clin. 1990;30:153-160.
19. Gurwitz JH, Avorn J, Bohn RL, Glynn RJ, Monane M, Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994;272:781-786.
20. SAS Institute Inc. The PHREG procedure. In: SAS Technical Report P-229: SAS/STAT Software: Changes and Enhancements. Release 6.07. Cary, NC: SAS Institute Inc; 1992:435-479.
21. Kitazawa Y, Horie T. The prognosis of corticosteroid-responsive individuals. Arch Ophthalmol. 1981;99:819-823.
22. Mygind N, Hansen I. Beclomethasone dipropionate aerosol effect on the adrenals in normal persons. Acta Allergol. 1973;28:211-218.
23. Wyatt R, Waschek J, Weinberger M, Sherman B. Effects of inhaled beclomethasone dipropionate and alternate-day prednisone on pituitary-adrenal function in children with chronic asthma. N Engl J Med. 1978;299:1387-1392.
24. Smith MJ, Hodson ME. Effects of long-term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax. 1983;38:676-681.
25. Ninan TK, Reid IW, Carter PE, Smail PJ, Russel G. Effects of high doses of inhaled corticosteroids on adrenal function in children with severe persistent asthma. Thorax. 1993;48:599-602.
26. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS. Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis. Drugs. 1980;19:397-411.
27. Bryson HM, Faulds D. Intranasal fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in allergic rhinitis. Drugs. 1992;43:760-775.
28. Clissold SP, Heel RC. Budesonide: a preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs. 1984;28:485-518.
29. Armaly MF. Effect of eorticosteroids on intraocular pressure and fluid dynamics, I: the effect of dexamethasone in the normal eye. Arch Ophthalmol. 1963;70:482-491.
30. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol. 1963;70:500-507.
31. Kass MA, Johnson T. Corticosteroid-induced glaucoma. In: Rich R, Shields MB, Krupin T, eds. The Glaucomas. St Louis, Mo: C V Mosby; 1989: 1161-1168.
32. Hernandez MR, Wenk EJ, Weinstein BI, et al. Glucocorticoid target cells in human outflow pathway: autopsy and surgical specimens. Invest Ophthalmol Vis Sci. 1983;24:1612-1616.
33. Weinreb RN, Bloom E, Baxter JD, et al. Detection of glucocorticoid receptors in cultured human trabecular cells. Invest Ophthalmol Vis Sci. 1981;21:403-407.
34. Rohen JW, Linner E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res. 1973;17:19-31.
35. Roll P, Benedikt O. Elektronenoptische Untersuchung des Trabekelwerkes bei einem Kortikosteroidglaukom. Klin Monatsbl Augenheilkd. 1979;174:421-428.
36. Francois J. Cortisone et tension oculaire. Ann Oculist. 1954;187:805-816.
37. Butcher JM, Austin M, McGalliard J, Bourke RD. Bilateral cataracts and glaucoma induced by long term use of steroid eye drops. BMJ. 1994;309: 43.
38. Goldmann H. Cortisone glaucoma. Arch Ophthalmol. 1962;68:621-626.
39. Burde RM, Becker B. Corticosteroid-induced glaucoma and cataracts in contact lens wearers. JAMA. 1970;213:2075-2077.
40. Brubaker RF, Halpin JA. Open-angle glaucoma associated with topical administration of flurandrenolide to the eye. Mayo Clin Proc. 1975;50:322-326.
41. Frenkel M. Blindness due to steroid induced glaucoma. Ill Med J. 1969;135:160-163.
42. Armaly MF. Characteristics of the steroid effect on intraocular pressure and aqueous dynamics. In: Paterson G, Miller SJH, Paterson GD, eds. Drug Mechanisms in Glaucoma, London, England: J & A Churchill Ltd; 1966:191-228.
43. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: the Baltimore Eye Survey. Arch Ophthalmol. 1991; 109:1090-1095.
44. Dielemans I, Vingerling JR, Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands: the Rotterdam Study. Ophthalmology. 1994;101:1851-1855.
45. Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet. 1995;345:41-44.
46. Rothman KJ. Modern Epidemiology. Boston, Mass: Little Brown & Co Inc; 1986:87.